Cellectis SA ( (CMVLF) ) has released its Q1 earnings. Here is a breakdown of the information Cellectis SA presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cellectis SA is a clinical-stage biotechnology company that leverages its pioneering gene-editing platform to develop cell and gene therapies, focusing on allogeneic CAR T immunotherapies for oncology and other therapeutic indications. The company recently reported its financial results for the first quarter of 2025, highlighting its strategic developments and financial performance.
In the first quarter of 2025, Cellectis announced ongoing progress in its clinical trials, including the Phase 1 studies of lasme-cel (UCART22) and eti-cel (UCART20x22) for treating specific types of cancer, with significant data readouts expected later in the year. Additionally, the company is advancing its research in non-viral gene editing and base editing, which will be presented at the upcoming ASGCT annual meeting.
Financially, Cellectis reported a cash position of $246 million, providing a runway into the second half of 2027. The company saw a notable increase in revenues and other income, totaling $12 million for the quarter, driven by progress in its partnership with AstraZeneca. However, the company reported a net loss of $18.1 million, primarily due to a decrease in net financial gains compared to the previous year.
Despite the financial loss, Cellectis continues to focus on its core programs and strategic partnerships, with a commitment to advancing its pipeline of product candidates. The management remains optimistic about the company’s future developments and its ability to sustain operations with its current financial resources.